Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Clin Virol ; 78: 89-92, 2016 May.
Article in English | MEDLINE | ID: mdl-27002710

ABSTRACT

BACKGROUND: HPV serology is important for studies of vaccine immunogenicity, but can not be performed in a comparable manner without international standardisation. OBJECTIVES: To find suitable candidate sera from naturally infected persons for use as International Standards (IS) for antibodies to high-risk HPVs, with priority for HPV-18. STUDY DESIGN: 946 healthy Thai women (median age 44, range 18-83) and 61 cervical cancer patients were screened using an HPV pseudovirion-Luminex assay to detect antibodies to genital (HPV-6,-11,-16,-18,-31,-33,-45,-52,-58,-68) and non-genital HPV types (HPV-5,-15,-32,-38 and -76). Suitable candidate sera should ideally be mono-specific (have reactivity against only one genital HPV) and have high antibody levels that are stable over time. RESULTS: Seroprevalences of HPV-16,-31,-52 and -58 were at least twice as high among cancer patients compared to healthy individuals. Thirteen healthy women who met the IS inclusion criteria in initial testing also consented to blood-bag donations. Donations from 2 women with high HPV-18 Ab titers were pooled to the HPV-18 candidate IS, later established as the WHO official IS for HPV antibodies. Sera that could potentially be used as candidate IS for other oncogenic HPVs have also been identified. CONCLUSIONS: In the Thai population, seroepidemiology implicated HPV types HPV-16,-31,-52 and -58 as particularly associated with cervical cancer. A well characterized cohort study has allowed sourcing of materials for an IS for HPV-18 antibodies and could conceivably be used for IS for other HPV types as well.


Subject(s)
Antibodies, Viral/blood , Human papillomavirus 18/immunology , Immunoassay/standards , Papillomavirus Infections/diagnosis , Papillomavirus Infections/immunology , Reference Standards , Adolescent , Adult , Aged , Cohort Studies , Female , Humans , Middle Aged , Papillomavirus Infections/epidemiology , Seroepidemiologic Studies , Thailand/epidemiology , Young Adult
2.
Cancer Epidemiol Biomarkers Prev ; 19(9): 2379-88, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20826835

ABSTRACT

BACKGROUND: Few human papillomavirus (HPV) seroprevalence studies have been carried out in women from low-resource countries. METHODS: Seroprevalence of antibodies against HPV16 and HPV18 was assessed in 7,074 women ≥15 years of age (median 44 years) from eight world areas. Serum antibodies against HPV16 and HPV18 were tested for using enzyme-linked immunosorbent assay. HPV DNA was assessed using a general primer GP5+/6+-mediated PCR. RESULTS: HPV16 and HPV18 seroprevalence both ranged from <1% (Hanoi, Vietnam) to >or=25% (Nigeria). Of women who were HPV16 or HPV18 DNA-positive, seropositivity for the same type was 39.8% and 23.2%, respectively. Seropositivity for either type was directly associated with markers of sexual behavior. HPV16 and/or 18 (HPV16/18)-seropositive women had an increased risk of having cytologic abnormalities only if they were also HPV DNA-positive. A high international correlation was found between HPV16/18 seroprevalence and overall HPV DNA prevalence (r = 0.81; P = 0.022). However, HPV16/18 seroprevalence was substantially higher than the corresponding DNA prevalence in all study areas (although to different extents) and, contrary to DNA, tended to increase from young to middle age, and then decline or remain fairly constant. In all study areas, the vast majority of the information on the burden of exposure to HPV16/18 derived from serology. CONCLUSIONS: The correlation between HPV DNA and HPV serology was not very good at an individual woman level, but high at a population level. IMPACT: HPV serology is a poor marker of current infection or related lesions, but it can contribute, together with DNA, in evaluating the variations in the burden of HPV infection worldwide.


Subject(s)
Human papillomavirus 16/immunology , Human papillomavirus 18/immunology , Papillomavirus Infections/epidemiology , Adult , Enzyme-Linked Immunosorbent Assay , Female , Global Health , Human papillomavirus 16/genetics , Human papillomavirus 18/genetics , Humans , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Seroepidemiologic Studies
3.
J Infect Dis ; 199(10): 1449-56, 2009 May 15.
Article in English | MEDLINE | ID: mdl-19351262

ABSTRACT

BACKGROUND: The aim of the present study was to estimate the prevalence of Kaposi sarcoma-associated herpesvirus (KSHV) in the female general population, to define geographic variation in and heterosexual transmission of the virus. METHODS: The study included 10,963 women from 9 countries for whom information on sociodemographic characteristics and reproductive, sexual, and smoking behaviors were available. Antibodies against KSHV that encoded lytic antigen K8.1 and latent antigen ORF73 were determined. RESULTS: The range of prevalence of KSHV (defined as detection of any antigen) was 3.81%-46.02%, with significant geographic variation noted. In Nigeria, the prevalence was 46.02%; in Colombia, 13.32%; in Costa Rica, 9.81%; in Argentina, 6.40%; in Ho Chi Minh City, Vietnam, 15.50%; in Hanoi, Vietnam, 11.26%; in Songkla, Thailand, 10%; in Lampang, Thailand, 8.63%; in Korea, 4.93%; and in Spain, 3.65%. The prevalence of KSHV slightly increased with increasing age among subjects in geographic areas where the prevalence of KSHV was high, such as Nigeria and Colombia, and it significantly decreased with increases in the educational level attained by subjects in those areas. KSHV was not statistically associated with age at first sexual intercourse, number of sex partners, number of children, patterns of oral contraceptive use, presence of cervical human papillomavirus DNA, or smoking status. CONCLUSIONS: The study provides comparable estimates of KSHV prevalence in diverse cultural settings across 4 continents and provides evidence that sexual transmission of KSHV is not a major source of infection in the general population.


Subject(s)
Glycoproteins/genetics , Sarcoma, Kaposi/genetics , Viral Proteins/genetics , Adult , Antigens, Viral/genetics , Colombia/epidemiology , Cross-Cultural Comparison , Female , Glycoproteins/isolation & purification , Herpesviridae Infections/epidemiology , Herpesviridae Infections/genetics , Herpesviridae Infections/transmission , Herpesvirus 8, Human , Humans , Middle Aged , Nigeria/epidemiology , Odds Ratio , Prevalence , Risk Factors , Sarcoma, Kaposi/epidemiology , Sexual Behavior , Thailand/epidemiology , Viral Proteins/isolation & purification
4.
Int J Epidemiol ; 37(3): 536-46, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18316350

ABSTRACT

BACKGROUND: Smoking increases the risk of squamous-cell carcinoma of the cervix, but it is not clear whether smoking increases the risk of acquisition or persistence of human papillomavirus (HPV) infection. METHODS: Information on smoking was collected from 10 areas in four continents among population-based, age-stratified random samples of women aged 15 years or older. HPV testing was performed using PCR-based enzyme immunoassay. Unconditional logistic regression was used to estimate odds ratios (OR) and corresponding 95% confidence intervals (CI) of being HPV-positive by smoking habits, adjusted for age and lifetime number of sexual partners. RESULTS: Ten thousand five hundred and seventy-seven women (mean age 41.4 years) were included. Among current smokers, the risk of being HPV-positive increased with smoking intensity, after allowing for lifetime number of sexual partners: ORs for <5, 5-14 and >/=15 cigarettes per day were 1.21 (95% CI 0.95-1.54), 1.39 (95% CI 1.04-1.87) and 2.01 (95% CI 1.32-3.08), respectively, as compared with never-smokers. The risk among former smokers (OR = 0.95, 95% CI 0.73-1.23) was similar to that among never-smokers. Analyses stratified by lifetime number of sexual partners showed a significant trend in risk only for women with one lifetime sexual partner. CONCLUSIONS: Our study suggests that current, though not former, smoking is associated with an increased prevalence of HPV, after allowance for sexual covariates. Among current smokers, HPV prevalence increased with smoking intensity, but a clear dose-response relationship was exclusively seen among women who declared one lifetime sexual partner.


Subject(s)
Papillomaviridae , Papillomavirus Infections/epidemiology , Smoking/adverse effects , Adolescent , Adult , DNA, Viral/analysis , Female , Humans , International Agencies , Logistic Models , Middle Aged , Papillomaviridae/genetics , Prevalence , Risk Assessment/methods , Sexual Partners
5.
Sex Transm Dis ; 34(8): 563-9, 2007 Aug.
Article in English | MEDLINE | ID: mdl-17417132

ABSTRACT

OBJECTIVES: Better information on the prevalence of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infection is needed in many world areas. STUDY DESIGN: Cross-sectional study of population-based samples of nonpregnant women aged 15 to 44 years in Nigeria, Colombia, Argentina, Vietnam (2 areas), China, Thailand (2 areas), Korea, and Spain. 5,328 consenting women aged 15 to 44 years participated. Exfoliated cervical cells were collected and testing for CT and NG and human papillomavirus (HPV) was done using PCR-based assays. RESULTS: Age-standardized CT prevalence ranged between 0.2% (95% confidence interval, CI: 0.0-0.7%) in Spain and 5.6% (95% CI: 3.4-7.8%) in Nigeria. NG ranged between 0% (with broad CIs) in several areas and 2.6% (95% CI: 1.0-4.2%) in Nigeria. Prevalence of CT in all areas combined was greater in women aged 15 to 24 (4.5; 95% CI: 3.4-5.8%) than 25 to 44 (2.6; 95% CI: 2.1-3.1%), whereas NG prevalence was similar in the 2 age groups (0.3%). The only significant risk factors were NG infection (for CT), CT infection (for NG) and infection with high-risk HPV types (for both). CONCLUSIONS: The prevalence of CT and, most notably, NG was relatively low in a variety of countries. Our findings, however, do not apply to subsets of high-risk women who are likely to be underrepresented in our population-based samples.


Subject(s)
Chlamydia Infections/epidemiology , Chlamydia trachomatis , Gonorrhea/epidemiology , Uterine Cervical Diseases/epidemiology , Adolescent , Adult , Asia/epidemiology , Chlamydia Infections/etiology , Chlamydia Infections/prevention & control , Colombia/epidemiology , Cross-Sectional Studies , Female , Gonorrhea/etiology , Gonorrhea/prevention & control , Humans , Neisseria gonorrhoeae , Nigeria/epidemiology , Prevalence , Risk Factors , Spain/epidemiology , Uterine Cervical Diseases/etiology , Uterine Cervical Diseases/prevention & control
6.
Cancer Epidemiol Biomarkers Prev ; 15(11): 2148-53, 2006 Nov.
Article in English | MEDLINE | ID: mdl-17119039

ABSTRACT

High parity, early age at first full-term pregnancy (FTP), and long-term oral contraceptive (OC) use increase cervical cancer risk, but it is unclear whether these variables are also associated with increased risk of acquisition and persistence of human papillomavirus (HPV) infection, the main cause of cervical cancer. Information on reproductive and menstrual characteristics and OC use were collected from 14 areas worldwide, among population-based, age-stratified random samples of women aged 15 years or older. HPV testing was done using PCR-based enzyme immunoassay. Unconditional logistic regression was used to estimate the odds ratios (OR) of being HPV-positive according to reproductive and menstrual factors and corresponding 95% confidence intervals (CI). When more than two groups were compared, floating CIs (FCI) were estimated. A total of 15,145 women (mean age, 40.9 years) were analyzed. Women with >or=5 FTPs (OR, 0.90; 95% FCI, 0.76-1.06) showed a similar risk of being HPV-positive compared with women with only one FTP (OR, 1.00; 95% FCI, 0.86-1.16). However, nulliparous women showed an OR of 1.40 (95% CI, 1.16-1.69) compared with parous women. Early age at first FTP was not significantly related to HPV positivity. HPV positivity was similar for women who reported >or=10 years of use of OCs (OR, 1.16; 95% FCI, 0.85-1.58) and never users of OCs (OR, 1.00; 95% FCI, 0.90-1.12). Our study suggests, therefore, that high parity, early age at first FTP, and long-term OC use are not associated with HPV prevalence, but rather these factors might be involved in the transition from HPV infection to neoplastic cervical lesions.


Subject(s)
Alphapapillomavirus/metabolism , Contraceptives, Oral/therapeutic use , Papillomavirus Infections/complications , Uterine Cervical Neoplasms/diagnosis , Uterine Cervical Neoplasms/etiology , Adolescent , Adult , Age Factors , Female , Humans , Immunoenzyme Techniques , Middle Aged , Papillomavirus Infections/epidemiology , Parity , Polymerase Chain Reaction , Pregnancy , Prevalence , Uterine Cervical Neoplasms/epidemiology
7.
Int J Cancer ; 119(11): 2677-84, 2006 Dec 01.
Article in English | MEDLINE | ID: mdl-16991121

ABSTRACT

An inverse relationship between age and human papillomavirus (HPV) prevalence has been reported in many developed countries, but information on this relationship is scarce in many other parts of the world. We carried out a cross-sectional study of sexually active women from the general population of 15 areas in 4 continents. Similar standardised protocols for women's enrolment, cervical specimen collection and PCR-based assays for HPV testing were used. HPV prevalence in different age groups was compared by study area. 18,498 women aged 15-74 years were included. Age-standardised HPV prevalence varied more than 10-fold between populations, as did the shape of age-specific curves. HPV prevalence peaked below age 25 or 35, and declined with age in Italy, the Netherlands, Spain, Argentina, Korea and in Lampang, Thailand and Ho Chi Minh, Vietnam. This was not the case in Songkla, Thailand nor Hanoi, Vietnam, where HPV prevalence was low in all age groups. In Chile, Colombia and Mexico, a second peak of HPV prevalence was detected among older women. In the poorest study areas in Asia (Shanxi, China and Dindigul, India), and in Nigeria, HPV prevalence was high across all age groups. The substantial differences observed in age-specific curves of HPV prevalence between populations may have a variety of explanations. These differences, however, underline that great caution should be used in inferring the natural history of HPV from age-specific prevalences.


Subject(s)
Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Adolescent , Adult , Aged , Cross-Sectional Studies , Female , Global Health , Humans , Middle Aged , Prevalence
8.
Cancer Epidemiol Biomarkers Prev ; 15(2): 326-33, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16492924

ABSTRACT

Human papillomavirus (HPV) is a sexually transmitted infection but it is unclear whether differences in transmission efficacy exist between individual HPV types. Information on sexual behavior was collected from 11 areas in four continents among population-based, age-stratified random samples of women of ages > or = 15 years. HPV testing was done using PCR-based enzyme immunoassay. Unconditional logistic regression was used to estimate odds ratios (OR) of being HPV positive and corresponding 95% confidence intervals (95% CI). Variables were analyzed categorically. When more than two groups were compared, floating confidence intervals were estimated by treating ORs as floating absolute risks. A total of 11,337 women (mean age, 41.9 years) were available. We confirmed that lifetime number of sexual partners is associated with HPV positivity (OR for > or = 2 versus 1, 1.86; 95% CI, 1.63-2.11) but the association was not a linear one for HPV18, 31, and 33 (i.e., no clear increase for > or = 3 versus 2 sexual partners). Women who had multiple-type infection and high-risk HPV type infection reported a statistically nonsignificant higher number of sexual partners than women who had single-type and low-risk type infections, respectively. Early age at sexual debut was not significantly related to HPV positivity. Husband's extramarital sexual relationships were associated with an OR of 1.45 (95% CI, 1.24-1.70) for HPV positivity in their wives after adjustment for age and lifetime number of women's sexual partners. We did not observe a significant association with condom use. Our study showed an effect of both women's and their husbands' sexual behavior on HPV positivity. Furthermore, it suggests some differences in the pattern of the association between sexual behavior and different HPV types.


Subject(s)
Condoms/statistics & numerical data , Papillomaviridae , Papillomavirus Infections/epidemiology , Sexual Behavior , Sexual Partners , Adolescent , Adult , Aged , Aged, 80 and over , Antibodies, Viral/blood , Female , Health Surveys , Herpesvirus 2, Human/immunology , Humans , International Agencies , Middle Aged , Odds Ratio , Prevalence
9.
J Infect Dis ; 187(8): 1246-56, 2003 Apr 15.
Article in English | MEDLINE | ID: mdl-12696004

ABSTRACT

To investigate the prevalence and determinants of human papillomavirus (HPV) infection, the primary cause of cervical cancer, we studied 1741 women >/=15 years of age from Lampang and Songkla, Thailand. Exfoliated cervical cells were collected for Papanicolaou smear screening and DNA detection of 36 different HPV types. Serum immunoglobulin G antibodies against L1 virus-like particles (anti-VLPs) of HPV-16, -18, -31, -33, and -58 were evaluated using enzyme-linked immunosorbent assay. Overall, 110 women (6.3%) were HPV DNA positive; the most common types were HPV-16, -52, and -72. The age-standardized prevalence of HPV DNA was higher among the 1035 women from Lampang (9.1%; 95% confidence interval [CI], 7.1-11.1) than among the 706 women from Songkla (3.9%; 95% CI, 2.3%-5.6%). Anti-VLPs were found in 21.8% of all women and were more frequent among women from Lampang (29.2%) than among women from Songkla (10.9%). Major risk factors for cervical HPV DNA were age <35 years, HSV-2 seropositivity, and having a husband with extramarital sexual partners.


Subject(s)
Papillomaviridae/isolation & purification , Papillomavirus Infections/epidemiology , Tumor Virus Infections/epidemiology , Adolescent , Adult , Aged , Antibodies, Viral/blood , DNA, Viral/genetics , DNA, Viral/isolation & purification , Female , Humans , Middle Aged , Papillomavirus Infections/immunology , Papillomavirus Infections/virology , Prevalence , Risk Factors , Thailand/epidemiology , Tumor Virus Infections/immunology , Tumor Virus Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...